The DOI matches its Crossref record; 210 of the 211 references it cites were found in a registry or an index.
The tubular hypothesis of nephron filtration and diabetic kidney disease
Open accessAbstract
Kidney size and glomerular filtration rate (GFR) often increase with the onset of diabetes, and elevated GFR is a risk factor for the development of diabetic kidney disease. Hyperfiltration mainly occurs in response to signals passed from the tubule to the glomerulus: high levels of glucose in the glomerular filtrate drive increased reabsorption of glucose and sodium by the sodium-glucose cotransporters SGLT2 and SGLT1 in the proximal tubule. Passive reabsorption of chloride and water also increases. The overall capacity for proximal reabsorption is augmented by growth of the proximal tubule, which (alongside sodium-glucose cotransport) further limits urinary glucose loss. Hyperreabsorption of sodium and chloride induces tubuloglomerular feedback from the macula densa to increase GFR. In addition, sodium-glucose cotransport by SGLT1 on macula densa cells triggers the production of nitric oxide, which also contributes to glomerular hyperfiltration. Although hyperfiltration restores sodium and chloride excretion it imposes added physical stress on the filtration barrier and increases the oxygen demand to drive reabsorption. Tubular growth is associated with the development of a senescence-like molecular signature that sets the stage for inflammation and fibrosis. SGLT2 inhibitors attenuate the proximal reabsorption of sodium and glucose, normalize tubuloglomerular feedback signals and mitigate hyperfiltration. This tubule-centred model of diabetic kidney physiology predicts the salutary effect of SGLT2 inhibitors on hard renal outcomes, as shown in large-scale clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a paracrine manner, adenosine constricts the afferent arteriole through the adenosine 1 receptor, thereby decreasing glomerular perfusion and hyperfiltration, a central mechanism for progressive glomerular injury (21,22).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [22]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Chronic kidney disease: global dimension and perspectives
Jha, V., Garcia-Garcia, G., Iseki, K., Li, Z., Naicker, S., Plattner, B., Saran, R., Wang, A. Y.-M., & Yang, C.-W. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60687-x · Cited by 4,383
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845
US Renal Data System 2016 Annual Data Report: Epidemiology of Kidney Disease in the United States
Saran, R., Robinson, B. M., Abbott, K. C., Agodoa, L. Y. C., Albertus, P., Ayanian, J. Z., Balkrishnan, R., Bragg‐Gresham, J. L., Cao, J., Chen, J. L. T., et al. (2017) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2016.12.004 · Cited by 2,192
Biology of Human Sodium Glucose Transporters
Wright, E. M., Loo, D. D. F., & Hirayama, B. A. (2011) · Physiological Reviews · doi:10.1152/physrev.00055.2009 · Cited by 1,430
Thomas, M. C., Brownlee, M., Suszták, K., Sharma, K., Jandeleit-Dahm, K. A. M., Zoungas, S., Rossing, P. R., Groop, P., & Cooper, M. E. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.18 · Cited by 1,335
Research works printed but not linked: 1
- Fu, Y., Gerasimova, M., Mayoux, E., Masuda, T. & Vallon, V. SGLT2 inhibitor empagliflozin increases renal NHE3 phosphorylation in diabetic Akita mice: possible implications for the prevention of glomerular hyperfiltration. Diabetes 63, (supplement 1), A132 (2014).
Cited by
Sorted by citations
Items 201–300 of 467
Liu, W., Ma, X., Gu, H., Li, H., Li, Z., & Wang, Y. (2022) · International Journal of Stroke · doi:10.1177/17474930221108278 · Cited by 10
Wei, S., Pan, X., Xiao, Y., Chen, R., & Wei, J. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1345293 · Cited by 10
Randomized, Placebo-Controlled Trial on the Renal and Systemic Hemodynamic Effects of Empagliflozin
Nielsen, S. F., Duus, C. L., Buus, N. H., Bech, J. N., & Mose, F. H. (2024) · Kidney International Reports · doi:10.1016/j.ekir.2024.10.019 · Cited by 11
Ding, S., Xu, J., Tong, J.-Y., Cheng, Y., Shi, L., Wei, W., Zhang, L., Zhang, J., Meng, B., Peng, X.-Y., et al. (2025) · Diabetologia · doi:10.1007/s00125-025-06385-8 · Cited by 10
Rodzoń-Norwicz, M., Kogut, P., Sowa-Kućma, M., & Gala‐Błądzińska, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146662 · Cited by 11
Korkmaz, Y., & Dik, B. (2023) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12975 · Cited by 11
Kidney oxygenation, perfusion and blood flow in people with and without type 1 diabetes
Laursen, J. C., Heinrich, N. S., Haddock, B., Rasmussen, I. K. B., Hansen, C. S., Larsson, H. B. W., Groop, P., Bjornstad, P., Frimodt‐Møller, M., Andersen, U. B., et al. (2022) · Clinical Kidney Journal · doi:10.1093/ckj/sfac145 · Cited by 9
Gholaminejad, A., Moein, S., Roointan, A., Mortazavi, M., Nouri, R., Mansourian, M., & Gheisari, Y. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-01940-w · Cited by 10
Did you know how SGLT2 inhibitors protect the kidney?
Layton, A. T., & Vallon, V. (2023) · Acta Physiologica · doi:10.1111/apha.14011 · Cited by 10
Self-citationLiu, C., Zhong, M., Jin, X., Zhu, J., Cheng, Y., Li, L., Xu, Q., Liu, Q., Ding, H. J., & Zhang, G. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02267-1 · Cited by 9
SGLT2 Inhibitors and Uric Acid Homeostasis
Zapf, A. M., & Woodward, O. M. (2024) · Gout Urate and Crystal Deposition Disease · doi:10.3390/gucdd2020014 · Cited by 10
Zhang, C., Qian, H., Cui, Y., Li, X., Cheng, Y., & Gao, L. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1422470 · Cited by 9
Role of urinary trace elements in diabetic kidney disease: a cross-sectional analysis
Gao, T., Lv, J., Lu, L., Guo, L., Tang, W., Shao, F., Zhu, S., Zhang, Y., Jia, R., Zhou, J., et al. (2024) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2024-004454 · Cited by 10
Song, S. M., Kim, M., Jang, M., Kim, M., Lee, K. H., Jeon, J., Jin, S., Jang, H. R., Huh, W., & Lee, J. E. (2025) · Kidney International Reports · doi:10.1016/j.ekir.2025.06.036 · Cited by 9
Wang, Y.-H., Chang, D., Zhao, Y.-Y., Tang, S. C. W., Zhao, M., & Chen, M. (2025) · Kidney International · doi:10.1016/j.kint.2025.10.009 · Cited by 9
Reconstruction of human metabolic models with large language models
Luo, J., Wang, H., Moyer, D. C., Guo, Z., Robinson, J. L., Gustafsson, J., Anton, M., Chen, Y., Kerkhoven, E. J., Nielsen, J., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2516511123 · Cited by 13
Mazzucato, M., Fioretto, P., & Avogaro, A. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14071 · Cited by 9
Luo, S., Li, Y., Li, S., Jiang, R., Deng, F., Liu, G., & Zhang, J. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.856427 · Cited by 9
Yi, Z., Yang, B., Wan, F., Lü, J., Liu, D., Lin, L., Xu, Y., Cen, Z., Fan, M., Liu, W., et al. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.118650 · Cited by 9
Siddiqui, S. H., Pitpitan, R., Boychev, B., Komnenov, D., & Rossi, N. F. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1436958 · Cited by 8
An, Y., & Zhang, H. (2025) · American Journal of Nephrology · doi:10.1159/000546079 · Cited by 10
Nephroprotective Mechanisms of SGLT2i: Beyond the Glucose-Lowering Effect
Mazzieri, A., & Marcon, L. M. R. (2025) · Biomedicines · doi:10.3390/biomedicines13092123 · Cited by 11
Sodium-Glucose Cotransporter 2 Inhibitors in Autosomal Dominant Polycystic Kidney Disease
Antoun, M. T. B., Borghol, A. H., Souvalian, L., Hadla, M., Abboud, G., Ghanem, A., Debeh, F. G. M., Mardirossian, J. M., Salih, M., Garimella, P. S., et al. (2025) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000943 · Cited by 9
Self-citationSun, S., Tian, F., Qiao, H., Xin, Q., Zhang, X., Song, N., Yan, Y., Liu, L., Wang, Y., Zhang, L., et al. (2025) · Advanced Materials · doi:10.1002/adma.202518331 · Cited by 9
Exploring the multifaceted role of TGF-β signaling in diabetic complications
Behl, T., Gupta, A., Sehgal, A., Singh, S., Sharma, N., Garg, M., Bhatia, S., Al‐Harrasi, A., Aleya, L., & BUNGAU, S. G. (2022) · Environmental Science and Pollution Research · doi:10.1007/s11356-022-19499-y · Cited by 9
Chang, S., Huang, W., Chapron, A., Quiñones, A. J. L., Wang, J., Isoherranen, N., Shen, D. D., Kelly, E. J., Himmelfarb, J., & Yeung, C. K. (2023) · Pharmaceutical Research · doi:10.1007/s11095-023-03594-x · Cited by 8
Zhang, Y., Gui, J., Chen, B., & Wan, Q. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1292397 · Cited by 8
Complement anaphylatoxins: Potential therapeutic target for diabetic kidney disease
Ma, J., Yiu, W. H., & Tang, S. C. W. (2024) · Diabetic Medicine · doi:10.1111/dme.15427 · Cited by 10
Wang, Z., Hao, D., Fang, D., Yu, J., Wang, X. Q., & Qin, G. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.785605 · Cited by 8
Xiang, W., Li, L., Qin, M., Li, L., Yu, H., Wang, F., Ni, S., Shen, A., Lu, H., Ni, H., et al. (2024) · British Journal of Pharmacology · doi:10.1111/bph.17347 · Cited by 7
Notch signaling in diabetic kidney disease: recent progress
Wang, Z., Tu, W., Long, Y.-N., Li, P., He, K.-Y., & Wu, J. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1537769 · Cited by 7
Empagliflozin alleviates type 2 diabetic renal fibrosis by inhibiting SLC7A7-mediated ferroptosis
Zhao, W., Jin, G., Sun, W., Wu, C., Yang, Q., Xue, L., & Ye, S. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01902-6 · Cited by 7
Fisiopatología renal y mecanismos farmacológicos de nefroprotección
Górriz, J. L., Górriz-Zambrano, C., & Pallarés‐Carratalá, V. (2023) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2023.102021 · Cited by 9
Incorporating Evidence and Guidelines for Personalized Care of Diabetes and Chronic Kidney Disease
Neumiller, J. J., Alicic, R. Z., & Tuttle, K. R. (2023) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2023.151427 · Cited by 7
Kanaoka, T., Wakui, H., Yano, Y., Nagasu, H., Kanegae, H., Nangaku, M., Hirakawa, Y., Nakagawa, N., Wada, J., Tsuruya, K., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15611 · Cited by 7
Li, Y., & Wang, J. (2024) · Journal of Asian Natural Products Research · doi:10.1080/10286020.2024.2364350 · Cited by 7
Renal ischemia/reperfusion induces prominent progressive kidney disease in diabetic mice
de Ponte, M. C., Cardoso, V. G., da Costa-Pessoa, J. M., Gonçalves, G. L., Pereira, B. M. V., Thieme, K., & Oliveira‐Souza, M. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00237.2023 · Cited by 7
Nicola, L. D., Cupisti, A., D’Alessandro, C., Gesualdo, L., Santoro, D., & Bellizzi, V. (2024) · Journal of Nephrology · doi:10.1007/s40620-024-02135-y · Cited by 7
ACSL4 predicts rapid kidney function decline in patients with diabetic kidney disease
Shen, R., Yu, X., Shi, C., Fang, Y., Dai, C., & Zhou, Y. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1499555 · Cited by 7
Liu, Y., Zhang, L., Wang, Y., Bai, L., Chen, S., Yang, J., & Wang, X. (2021) · DNA and Cell Biology · doi:10.1089/dna.2021.0627 · Cited by 8
Li, X. Q., Zhang, J. X., Li, L., Wu, Q. Y., Ruan, X. Z., Chen, P. P., & Ma, K. L. (2025) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000681 · Cited by 6
Shi, C., Wang, X., Qin, S., He, A., Wu, X., Ke, Q., Shen, R., Wan, Y., Wang, L., Xiao, Y., et al. (2025) · Diabetologia · doi:10.1007/s00125-025-06519-y · Cited by 7
Tsopmejio, I. S. N., Tang, S., Gao, X.-F., Liu, Z., Li, X., Qi, M.-H., Zhu, H., Wang, Z., & Li, W. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115378 · Cited by 6
You, X.-L., Zhao, M., Liu, Y., Tang, Z., Zhao, Y.-T., YanLiu, & Song, Z. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.155160 · Cited by 6
Glomerular pressure and tubular oxygen supply: a critical dual target for renal protection
Masuda, T., & Nagata, D. (2024) · Hypertension Research · doi:10.1038/s41440-024-01944-9 · Cited by 7
Kidney Adaptations Prevent Loss of Trace Elements in Wistar Rats with Early Metabolic Syndrome
Sánchez‐Solís, C. N., Hernández-Fragoso, H., Aburto-Luna, V., Barbier, O. C., Díaz, A., Brambila, E., & Treviño, S. (2020) · Biological Trace Element Research · doi:10.1007/s12011-020-02317-2 · Cited by 6
Sugiyama, S., Yoshida, A., Hieshima, K., Kurinami, N., Jinnouchi, K., Tanaka, M., Suzuki, T., MIYAMOTO, F., Kajiwara, K., Jinnouchi, T., et al. (2020) · Journal of Clinical Medicine Research · doi:10.14740/jocmr4351 · Cited by 6
Eita, M. A. H., Ashour, R. H., & El-Khawaga, O. Y. (2022) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12781 · Cited by 6
Wang, Z., Yu, J., Hao, D., Liu, X., & Wang, X. Q. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.965379 · Cited by 6
Zhang, D., Pan, J., Zhou, H., & Cao, Y. (2020) · Zoological Letters · doi:10.1186/s40851-020-00159-3 · Cited by 6
Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors
Kataria, A., & Argyropoulos, C. (2022) · Springer eBooks · doi:10.1007/978-3-030-86020-2_25 · Cited by 6
Totally tubular, dude: rethinking DKD pathogenesis in the wake of SGLT2i data
Yu, S. M.-W., Leventhal, J. S., & Cravedi, P. (2020) · Journal of Nephrology · doi:10.1007/s40620-020-00868-0 · Cited by 6
PM2.5 Exposure Induces Glomerular Hyperfiltration in Mice in a Gender-Dependent Manner
Wang, H., Ma, L., Guo, Y., Ren, L., Li, G., & Sang, N. (2024) · Toxics · doi:10.3390/toxics12120878 · Cited by 5
Diabetic nephropathy: Pathophysiology and potential therapeutic role of plant extracts
Mir, M. N., Malik, I. A., Naik, R. A., Singh, S., Hurra, A. R., Wani, Z., Shah, R., & Lone, Y. (2025) · Endocrine and Metabolic Science · doi:10.1016/j.endmts.2025.100263 · Cited by 5
Baldelomar, E. J., Morozov, D., Wilson, L. D., Eldeniz, C., An, H., Charlton, J. R., Bauer, A. Q., Keilholz, S. D., Hulbert, M. L., & Bennett, K. M. (2024) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00423.2023 · Cited by 5
Song, R., Hou, Q., Zhang, X., Zhao, W., Liu, G., Li, M., Zhang, X., & Ji, L. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1376850 · Cited by 5
Jiang, L., Jian, J., Sai, X., & Wu, X. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0233 · Cited by 5
Crespo‐Masip, M., Goodluck, H. A., Kim, Y. C., Oe, Y., Roach, A. M., Kanoo, S., Lopez, N., Zhang, H., Badal, S. S., & Vallon, V. (2025) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00031.2025 · Cited by 5
Self-citationElhenawy, Y. I., Abdelmaksoud, A. A., Ismail, E. A. R., Elashmawy, Z. M., & Sallam, D. E. D. (2025) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2025.2492762 · Cited by 5
Protecting the Kidney: The Unexpected Logic of Inhibiting a Glucose Transporter
Vallon, V., & Kim, Y. C. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2651 · Cited by 5
Self-citationNovel Drugs for the Management of Diabetes Kidney Transplant Patients: A Literature Review
Valencia-Morales, N. D., Cubillo, B. R., Loayza-López, R. K., de la Higuera, M. Á. M., & Sánchez-Fructuoso, A. I. (2023) · Life · doi:10.3390/life13061265 · Cited by 5
Renal Protection and Safety of Sodium-glucose Cotransporter-2 Inhibitors in Chronic Kidney Disease
Zhou, T., Yao, K., Xie, Y., Lin, Y., Wang, J., & Chen, X. (2023) · Current Pharmaceutical Design · doi:10.2174/1381612829666230804103643 · Cited by 5
Shi, Y., Guo, Z., Liu, F., Pan, S., Gao, D., Zhou, S., Liu, Z., Wang, F., Liu, D., & Liu, Z. (2023) · Aging · doi:10.18632/aging.205107 · Cited by 5
Granda, M. L., Huang, W., Yeung, C. K., Isoherranen, N., & Kestenbaum, B. R. (2023) · Clinical and Translational Science · doi:10.1111/cts.13678 · Cited by 5
Cheval, L., Poindessous, V., Sampaio, J. L., Crambert, G., & Pallet, N. (2024) · Function · doi:10.1093/function/zqae016 · Cited by 5
Rastogi, A., Collins, A. K., Kelepouris, E., Kotzker, W. R., Middleton, J. P., Rajpal, M., Roy‐Chaudhury, P., & Chertow, G. M. (2024) · Journal of Primary Care & Community Health · doi:10.1177/21501319241259905 · Cited by 5
Nayak, S., Rathore, V., Bharati, J., & Sahu, K. K. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.2028620 · Cited by 5
New insights and advances of sodium-glucose cotransporter 2 inhibitors in heart failure
Li, J., Zhou, L., & Gong, H. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.903902 · Cited by 6
SGLT2 Inhibitor: an Emerging Pillar in Heart Failure Therapeutics?
GEAVLETE, B. F., Popescu, R.-I., Iordache, V., Georgescu, D. E., & Geavlete, P. A. (2023) · MAEDICA – a Journal of Clinical Medicine · doi:10.26574/maedica.2023.18.1.102 · Cited by 7
Moriconi, D., Rovera, C., Raggi, F., Armenia, S., Bruno, R. M., & Solini, A. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf334 · Cited by 4
Construction, evaluation, and applications of renal barrier-on-a-chip system
Naren, T., Lv, W., Aazmi, A., Wang, Y., Yu, H., Lee, J. Y., Yang, H., Yu, M., Jiang, X., Yang, H., et al. (2026) · Bioactive Materials · doi:10.1016/j.bioactmat.2025.12.032 · Cited by 4
Trambas, I. A., Bowen, L., Thallas‐Bonke, V., Snelson, M., Sourris, K. C., Laskowski, A., Tauc, M., Rubera, I., Zheng, G., Harris, D. C. H., et al. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103601 · Cited by 4
Goodluck, H., Zemljic‐Harpf, A. E., Galdino, O. A., Kanoo, S., Lopez, N., Kim, Y., & Vallon, V. (2025) · Physiological Reports · doi:10.14814/phy2.70217 · Cited by 5
Self-citationXiong, X., Feng, X., Wei, W., Zhu, Y., Li, M., & Sun, K. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c11296 · Cited by 4
Huang, J., Pang, D., Fan, C., Yang, G., Chen, J., & Chen, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1627173 · Cited by 4
Carrera‐Bastos, P., Muskiet, M. H. A., Ordóñez, F. M., Pruimboom, L., Lucía, A., Luque, R. M., & Muskiet, F. A. J. (2025) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-025-09996-z · Cited by 5
Gao, C., Cai, X., Li, J., Jiang, J., Bo, Q. I. A. N., Yang, R., & Xiong, F. (2026) · Burns · doi:10.1016/j.burns.2026.107874 · Cited by 4
Kim, Y. C., Meng, C., Kanoo, S., Thomson, S. C., Karihaloo, A., & Vallon, V. (2026) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00109.2026 · Cited by 4
Self-citationNew Strategies for Volume Control in Patients with Diabetes Mellitus, a Narrative Review
Gérard, A. O., Laurain, A., Sicard, A., Merino, D., Pathak, A., Drici, M., Favrè, G., & Esnault, V. L. M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081569 · Cited by 3
Miñana, G., de la Espriella, R., Palau, P., Amiguet, M., Seller, J., Pinilla, J. M. G., Núñez, E., Górriz, J. L., Valle, A., Sanchís, J. M., et al. (2023) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2023.03.007 · Cited by 4
High glucose couples DJ-1 with PTEN to activate PDGFRβ for renal proximal tubular cell injury
Das, F., Ghosh‐Choudhury, N., Kasinath, B. S., Sharma, K., & Choudhury, G. G. (2025) · PLoS ONE · doi:10.1371/journal.pone.0311828 · Cited by 4
Vlasschaert, C., Sidhu, B., & Silver, S. A. (2021) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000703 · Cited by 5
The Physiological Effects of Visfatin on Immune Response and Inflammatory Impacts on Nephropathy.
Obaidi, R. M. S. A. (2021) · PubMed Central · doi:10.22092/ari.2021.355463.1688 · Cited by 4
Protective Effect of Adalimumab on Diabetic Nephropathy by Regulating TNF-α Signal Pathway
Ding, Z., Jiang, H., Fan, Y., & Sun, G. (2021) · Iranian Journal of Public Health · doi:10.18502/ijph.v50i12.7936 · Cited by 4
Miyaoka, Y., Moriyama, T., Saito, S., Rinno, S., Kato, M., Tsujimoto, R., Suzuki, R., China, R., Nagai, M., & Kanno, Y. (2024) · The Nephron journals/Nephron journals · doi:10.1159/000538589 · Cited by 4
Emerging roles of Sodium-glucose cotransporter 2 inhibitors in Diabetic kidney disease
Gan, T., Song, Y., Guo, F., & Qin, G. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-07758-7 · Cited by 4
Das, F., Ghosh‐Choudhury, N., Kasinath, B. S., Sharma, K., & Choudhury, G. G. (2024) · Experimental Cell Research · doi:10.1016/j.yexcr.2024.114116 · Cited by 3
Pelepenko, L. E., Hewitt, B. J., de Oliveira, R. B., Moraes, B. F., Coraça-Huber, D. C., Janini, A. C. P., & Marciano, M. A. (2025) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2025.138580 · Cited by 3
Hu, Z.-Y., Sun, Q.-H., Ma, Y., Wang, Y.-K., Chen, C., Liu, X., Ma, X.-H., & Liu, X. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117440 · Cited by 3
Pan, X., Mowdawalla, C., Bagnato, S., Pessin, J. E., Vallon, V., & Hussain, M. M. (2025) · Nature Communications · doi:10.1038/s41467-025-65402-x · Cited by 3
Self-citationPyroptosis-induced tissue damage in kidney disease
Zhang, Z., Li, X., Han, Y., & Zhang, M. (2025) · Renal Failure · doi:10.1080/0886022x.2025.2590328 · Cited by 5
Hua, J., Wang, Q., Liu, Y., Luo, S., Shi, A., Yan, Z., Zhang, J., Gu, W., Zhu, L., Zhang, Y., et al. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03173-5 · Cited by 3
Reference intervals for kidney tubular secretion markers in the general population: The HUNT3 study
Øvrehus, M. A., Kristiansen, K. A., Langlo, K. A. R., Garimella, P. S., Ix, J. H., Shlipak, M. G., Bruheim, P., & Hallan, S. I. (2026) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/00045632261454284 · Cited by 3
Chen, L., Zhang, L., & Zhou, N. (2026) · International Urology and Nephrology · doi:10.1007/s11255-026-05210-4 · Cited by 3
van der Hoek, S., & Stevens, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.837993 · Cited by 3
Patel, R., Fu, Y., Khang, S., Benardeau, A. M., Thomson, S. C., & Vallon, V. (2022) · The Nephron journals/Nephron journals · doi:10.1159/000526934 · Cited by 3
Self-citationGosai, S. A., Qadree, A. K., Singh, A. P., Chavan, M., & Oso, B. I. (2023) · Clinical Medicine And Health Research Journal · doi:10.18535/cmhrj.v3i3.170 · Cited by 3
Rashid, S. A., Madar, I. H., Misbah, I., Dhanabalan, K., Balasubramanian, R., & Maideen, N. M. P. (2025) · Ibnosina Journal of Medicine and Biomedical Sciences · doi:10.1055/s-0045-1805026 · Cited by 4
da Silva, G. C., Diniz, T. F., Aires, R. D., Peruchetti, D. B., da Silva, R., Vieira, M. A. R., & Lemos, V. S. (2025) · Gerontology · doi:10.1159/000547620 · Cited by 3
SGLT-2-gátló kezelés diabeteses és nem diabeteses vesebetegségben
Molnár, G. A., Sélley, E., & Wittmann, I. (2021) · Diabetologia Hungarica · doi:10.24121/dh.2021.14 · Cited by 3
Metadata
- Authors
- Vallon, V., & Thomson, S. C.
- Affiliations
- University of California San Diego (US)
- Corresponding author
- Vallon, Volker
- Venue
- Nature Reviews Nephrology
- Published
- 2020-03-09
- Volume
- 16
- Issue
- 6
- Pages
- 317-336
- ISSN
- 1745-8323 (ISSN-L)
- 1759-5061
- 1759-507X
- PMC
- PMC7242158
- OpenAlex
- W3009930262
- Cited by
- 465
- References
- 211
- Citations by year
- 2026: 80 · 2025: 75 · 2024: 79 · 2023: 70 · 2022: 79 · 2021: 55 · 2020: 24
- FWCI
- 9.19
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature Reviews Nephrology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (1rf1ag061296-01a1)
- National Institute on Aging (RF1-AG061296)
- National Heart, Lung, and Blood Institute (R01HL142814)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK079337, R01DK106102, R01DK112042)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- diabetic nephropathy, glomerular hyperfiltration, tubuloglomerular feedback, SGLT2, SGLT1, proximal tubular reabsorption, macula densa, nitric oxide, renal fibrosis, SGLT2 inhibitors, glomerular filtration rate
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Chlorides, Diabetes Mellitus, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Fibrosis, Glomerular Filtration Rate, Glucose, Humans, Hypertrophy, Inflammation, Kidney Glomerulus, Kidney Tubules, Nephrons, Nitric Oxide, Sodium, Cellular Senescence, Sodium-Glucose Transporter 1, Sodium-Glucose Transporter 2, Glomerular Filtration Barrier, Renal Reabsorption
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
